SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
First Wave BioPharma, Inc. (FWBI) , forward earnings yield 15.55%.
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
- Forward P/E 6.4
Overall SharesGrow Score: 41/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — FWBI
Valuation Multiples
P/E (TTM)0.0
Forward P/E6.4
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-5.33
Forward EPS (Est.)$0.46
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield15.55%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$-1,261.75 |
$0.00 |
$-5.93M |
- |
| 2016 |
$-4,711.55 |
$0.00 |
$-14.59M |
- |
| 2017 |
$-2,192.53 |
$0.00 |
$-11.1M |
- |
| 2018 |
$-1,840.81 |
$0.00 |
$-13.53M |
- |
| 2019 |
$-29,238.40 |
$0.00 |
$-15.61M |
- |
| 2020 |
$-57,194.10 |
$0.00 |
$-38.72M |
- |
| 2021 |
$-27,799.20 |
$0.00 |
$-59.08M |
- |
| 2022 |
$-461.72 |
$0.00 |
$-16.58M |
- |
| 2023 |
$-46.96 |
$0.00 |
$-15.79M |
- |
| 2024 |
$-5.33 |
$0.00 |
$-18.06M |
- |
